Novartis Restresses China Commitment As It Outlines 2016 Plans
This article was originally published in PharmAsia News
Novartis will celebrate the 20th anniversary of the establishment of its independent operations in China this year, and has taken the opportunity to stress its ongoing commitment to this key market in line with its global core strategy, and despite the weaker economic outlook in the country, where it has plans to develop three new key therapeutic areas during 2016.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.